Literature DB >> 11278977

COL5A1 exon 14 splice acceptor mutation causes a functional null allele, haploinsufficiency of alpha 1(V) and abnormal heterotypic interstitial fibrils in Ehlers-Danlos syndrome II.

P Bouma1, W A Cabral, W G Cole, J C Marini.   

Abstract

We studied four affected individuals from a family of three generations with Ehlers-Danlos Syndrome II. Type V collagen transcripts of affected individuals were screened by reverse transcriptase-polymerase chain reaction. Amplification of the exon 9-28 region of alpha1(V) yielded normal and larger products from the proband. Sequencing of cDNA revealed a 100-base pair insertion from the 3'-end of intron 13 between exons 13 and 14 in one allele. The genomic defect was identified as an A(-2)--> G substitution at the exon 14 splice acceptor site. A cryptic acceptor site -100 nucleotide within intron 13 is used instead of the mutant splice site. The insertion shifts the reading frame +1 and results in a stop codon within exon 17. The mutant transcript was much less abundant than normal allele product in untreated cultured fibroblasts but was approximately equimolar in cycloheximide-treated cells, suggesting that the mutation causes nonsense-mediated decay of mRNA. By RNase protection experiments, the level of mutant transcript was determined to be 8% that of the normal transcript in untreated proband fibroblasts. Relative to type I collagen, proband fibroblasts secreted only 65% of the amount of type V collagen secreted by normal controls. Selective salt precipitation of proband secreted collagen provided supportive evidence that the alpha chain composition of type V collagen remains alpha1(V)(2)alpha2(V) even in the context of alpha1(V) haploinsufficiency. Type V collagen incorporates into type I collagen fibrils in the extracellular matrix and is thought to regulate fibril diameter. Transmission electron micrographs of type I collagen fibrils in a proband dermal biopsy showed greater heterogeneity in fibril diameter than in a matched control. The proband had a greater proportion of both larger and smaller fibrils and occasional fibrils with a cauliflower configuration. Unlike the genotype/phenotype relationship seen for type I collagen defects and osteogenesis imperfecta, the null allele in this family appears to cause clinical features similar to those seen in cases with structural alterations in type V collagen.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11278977     DOI: 10.1074/jbc.M011742200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Development of a functional skin matrix requires deposition of collagen V heterotrimers.

Authors:  Hélène Chanut-Delalande; Christelle Bonod-Bidaud; Sylvain Cogne; Marilyne Malbouyres; Francesco Ramirez; Agnès Fichard; Florence Ruggiero
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

2.  Hemizygous deletion of COL3A1, COL5A2, and MSTN causes a complex phenotype with aortic dissection: a lesson for and from true haploinsufficiency.

Authors:  Janine Meienberg; Marianne Rohrbach; Stefan Neuenschwander; Katharina Spanaus; Cecilia Giunta; Sira Alonso; Eliane Arnold; Caroline Henggeler; Stephan Regenass; Andrea Patrignani; Silvia Azzarello-Burri; Bernhard Steiner; Anders O H Nygren; Thierry Carrel; Beat Steinmann; Gábor Mátyás
Journal:  Eur J Hum Genet       Date:  2010-07-21       Impact factor: 4.246

3.  Regulation of collagen fibril nucleation and initial fibril assembly involves coordinate interactions with collagens V and XI in developing tendon.

Authors:  Richard J Wenstrup; Simone M Smith; Jane B Florer; Guiyun Zhang; David P Beason; Robert E Seegmiller; Louis J Soslowsky; David E Birk
Journal:  J Biol Chem       Date:  2011-04-05       Impact factor: 5.157

4.  Collagen V is a dominant regulator of collagen fibrillogenesis: dysfunctional regulation of structure and function in a corneal-stroma-specific Col5a1-null mouse model.

Authors:  Mei Sun; Shoujun Chen; Sheila M Adams; Jane B Florer; Hongshan Liu; Winston W-Y Kao; Richard J Wenstrup; David E Birk
Journal:  J Cell Sci       Date:  2011-12-08       Impact factor: 5.285

5.  Rare autosomal recessive cardiac valvular form of Ehlers-Danlos syndrome results from mutations in the COL1A2 gene that activate the nonsense-mediated RNA decay pathway.

Authors:  Ulrike Schwarze; Ryu-Ichiro Hata; Victor A McKusick; Hiroshi Shinkai; H Eugene Hoyme; Reed E Pyeritz; Peter H Byers
Journal:  Am J Hum Genet       Date:  2004-04-09       Impact factor: 11.025

6.  Biased exon/intron distribution of cryptic and de novo 3' splice sites.

Authors:  Jana Královicová; Mikkel B Christensen; Igor Vorechovský
Journal:  Nucleic Acids Res       Date:  2005-09-01       Impact factor: 16.971

7.  Aberrant 3' splice sites in human disease genes: mutation pattern, nucleotide structure and comparison of computational tools that predict their utilization.

Authors:  Igor Vorechovský
Journal:  Nucleic Acids Res       Date:  2006-09-08       Impact factor: 16.971

8.  Clinical and molecular characterization of 40 patients with classic Ehlers-Danlos syndrome: identification of 18 COL5A1 and 2 COL5A2 novel mutations.

Authors:  Marco Ritelli; Chiara Dordoni; Marina Venturini; Nicola Chiarelli; Stefano Quinzani; Michele Traversa; Nicoletta Zoppi; Annalisa Vascellaro; Anita Wischmeijer; Emanuela Manfredini; Livia Garavelli; Piergiacomo Calzavara-Pinton; Marina Colombi
Journal:  Orphanet J Rare Dis       Date:  2013-04-12       Impact factor: 4.123

Review 9.  Vascular phenotypes in nonvascular subtypes of the Ehlers-Danlos syndrome: a systematic review.

Authors:  Sanne D'hondt; Tim Van Damme; Fransiska Malfait
Journal:  Genet Med       Date:  2017-10-05       Impact factor: 8.822

10.  Identification of Two Independent COL5A1 Variants in Dogs with Ehlers-Danlos Syndrome.

Authors:  Anina Bauer; John F Bateman; Shireen R Lamandé; Eric Hanssen; Shannon G M Kirejczyk; Mark Yee; Ali Ramiche; Vidyha Jagannathan; Monika Welle; Tosso Leeb; Fiona L Bateman
Journal:  Genes (Basel)       Date:  2019-09-21       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.